By Ludwig Burger FRANKFURT (Reuters) – Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday. The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer. Among AskBio’s most advanced projects are early tests on volunteers of prospective treatments against Pompe disease – a ...
Source:https://www.medicalnewstoday.com/articles/327291.php#1 Using mouse models of Alzheimer’s disease, researchers have been looking into a new approach to slow down the progression of this neurodegenerative disease — a ketone ester-rich diet.Could a new therapeutic approach help slow down Alzheimer’s disease? Researchers from the NIH investigate.To get the energy it needs to function correctly, the body usually relies on glucose (a simple sugar), which results from the digestion of carbohydrates. When there is not enough glucose to rely on, the body will burn fat instead. This is a process called ketosis, and it is the principle that ketogenic — or keto — diets rely on.Keto diets are typically low in carbohydrates and high in fats, and this imbalance in resources produces ketosis. But there is also another way of inducing ketosis that does not involve making this dietary shift. It involves taking supplements containing ketone ester, which have the same effect. Researchers have ...
Physical therapy rehabilitation includes a number of treatments applied to people suffering from any kind of injury or pain. Physical therapists use various kinds of equipment to rehabilitate patients to carry out normal movements and functions with their limbs and other body parts.
Neurodegenerative diseases are plenty in number, but to find the ultimate research is still ongoing worldwide. One company involved in this process is Suven Life Sciences. They have discovered novel chemical entities responsible for the treatment of neurodegenerative diseases, which were claimed for patenting.
23andMe declared an investment of $300 million on Wednesday, made by GlaxoSmithKline to attain special access to their DNA database.
San Francisco based Verge Genomics, the Neuroscience based drug discovery company launched in 2015, has raised $32 million in early venture capital financing to bring its AI-generated compounds against Parkinson’s disease and amyotrophic lateral sclerosis (ALS) to clinics within the next three years.
A research team from Tel Aviv University suggested that red wine and green tea could treat certain congenital metabolic diseases, by blocking toxic metabolite formations. Since people with inborn metabolic disorders are born with a defective gene, it leads to a critical enzyme deficiency. Since there is no cure, many patients with congenital metabolic disorders are required to follow a lifelong strict diet.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
With a view of gathering mHealth data through a wearable from over 800 people with Parkinson’s disease, a project has been unveiled by the Michael J Fox Foundation which has been doing pioneering work in Parkinson’s disease.
Mayo Clinic researchers found success with an mHealth app - EpiFinder, which can diagnose Epilepsy (A disruption in which nerve cell activity in the brain is disturbed, causing seizures). During recent research conducted at Mayo Clinic, the Epifinder app recognized epilepsy in almost 87percent of the cases.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.